118779-92-3

Usage

Uses

Used in Pharmaceutical Industry:
(6-(Dimethylamino)-5-methylpyrimidin-4-yl)methanol is used as a building block for the synthesis of other organic compounds, particularly those with potential pharmaceutical applications. Its unique structure may contribute to the development of new drugs or drug candidates.
Used in Chemical Synthesis:
In the chemical industry, (6-(Dimethylamino)-5-methylpyrimidin-4-yl)methanol is used as a starting material or intermediate in the synthesis of various organic compounds. Its reactivity and structural features make it a valuable component in the creation of complex molecules.
Used in Research and Development:
As a compound with potential biological activity, (6-(Dimethylamino)-5-methylpyrimidin-4-yl)methanol is used in research and development for exploring its possible applications in medicine. Ongoing studies aim to understand its interactions with biological systems and its potential therapeutic effects.

Upstream product

• 759-65-9 diethyl oxalpropionate 
• 1615714-07-2 ethyl 6-(dimethylamino)-5-methylpyrimidine-4-carboxylate 
• 1232059-52-7 ethyl 6-chloro-5-methyl-pyrimidine-4-carboxylate 
• 76480-52-9 ethyl 6-hydroxy-5-methyl-pyrimidine-4-carboxylate 

Relevant academic research and scientific papers

AZAINDOLE COMPOUNDS, SYNTHESIS THEREOF, AND METHODS OF USING THE SAME

The invention provides compounds of formula (I) and methods of treating a Mycobacterium infection or tuberculosis, or inhibiting DprE1 with the same.

Lead optimization of 1,4-azaindoles as antimycobacterial agents

In a previous report, we described the discovery of 1,4-azaindoles, a chemical series with excellent in vitro and in vivo antimycobacterial potency through noncovalent inhibition of decaprenylphosphoryl-β-d-ribose-2′- epimerase (DprE1). Nevertheless, high mouse metabolic turnover and phosphodiesterase 6 (PDE6) off-target activity limited its advancement. Herein, we report lead optimization of this series, culminating in potent, metabolically stable compounds that have a robust pharmacokinetic profile without any PDE6 liability. Furthermore, we demonstrate efficacy for 1,4-azaindoles in a rat chronic TB infection model. We believe that compounds from the 1,4-azaindole series are suitable for in vivo combination and safety studies.

Pyrimidylalkylthio benzimidale compounds, pharmaceutical compositions and use

This invention relates to 2- and 4-pyrimidinylmethylsulphinyl(and thio)benzimidazoles in which the pyrimidyl group is substituted by an optionally substituted amino group. These compounds inhibit exogenously and endogenously stimulated gastric acid secretion.